Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | GNPAT | O15228 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20530 | 1.00 | FOLH1 (0.62) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| SCHEMBL20529 | 1.00 | FOLH1 (0.62) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| SCHEMBL31621383 | 0.98 | FOLH1 (0.60) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15669796 | 0.98 | FOLH1 (0.60) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| SCHEMBL31621379 | 0.98 | FOLH1 (0.60) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| SCHEMBL31621381 | 0.98 | FOLH1 (0.60) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| SCHEMBL16238796 | 0.98 | FOLH1 (0.60) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| Ethylene SCHEMBL28796153 | 0.96 | FOLH1 (0.58) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| Glycine SCHEMBL17203937 | 0.95 | FOLH1 (0.61) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 | |
| Glycine SCHEMBL28267531 | 0.95 | FOLH1 (0.61) | FOLH1SIRT6SIRT1GNPATSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098441-A1 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING POLYPEPTIDE CONJUGATES | SUZHOU SMARTNUCLIDE BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-15 | — | — | WO | claimed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | claimed |
| US-20240327511-A1 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-10-03 | — | — | US | claimed |
| US-20240002501-A1 | ANTI-L1-CAM ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-01-04 | — | — | US | claimed |
| US-20230348853-A1 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-11-02 | — | — | US | claimed |
| CN-116801889-A | Compositions comprising ex vivo armed T cells with multispecific antibodies and uses thereof | 纪念斯隆凯特琳癌症中心 | 2023-09-22 | — | — | CN | claimed |
| US-20230270857-A1 | COMPOSITIONS INCLUDING EX VIVO ARMED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-08-31 | — | — | US | claimed |
| US-20230235087-A1 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-07-27 | — | — | US | claimed |
| EP-4188442-A2 | COMPOSITIONS INCLUDING EX VIVO ARMED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116194133-A | anti-GD 2 SADA conjugates and uses thereof | 纪念斯隆凯特琳癌症中心 | 2023-05-30 | — | — | CN | claimed |
| US-7026345-B2 | Resolution of 3-amino alkylnitriles | PFIZER INC. (US) | 2006-04-11 | — | — | US | claimed |
| US-20050107453-A1 | Resolution of 3-amino alkylnitriles | PFIZER INC. | 2005-05-19 | — | — | US | claimed |
| WO-2005040097-A1 | RESOLUTION OF 3-AMINO ALKYLNITRILES | PFIZER PRODUCTS INC. (US) | 2005-05-06 | — | — | WO | claimed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | claimed |
| EP-0618809-A1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | claimed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | claimed |
| EP-0618809-A4 | BRADYKININ TYPE PEPTIDES. | SCIOS NOVA INC (US) | 1994-07-28 | — | — | EP | claimed |
| WO-1994008607-A1 | NOVEL PSEUDOPEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS NOVA INC. (US) | 1994-04-28 | — | — | WO | claimed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992018155-A1 | BRADYKININ TYPE PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348853-A1 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | CD4, LY96, CD81 | FOLH1 185/4885SIRT6 4647/4885SIRT1 4774/4885 |
| US-20050107453-A1 | Resolution of 3-amino alkylnitriles | AADAT, AANAT, AAAS | FOLH1 3707/4885SIRT6 2767/4885SIRT1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.